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Abstract
Introduction:  The  guidelines  on  allergic  rhinitis  aim  to  update  knowledge  about  the  disease  and
care for  affected  patients.  The  initiative  called  ‘‘Allergic  Rhinitis  and  its  Impact  on  Asthma’’,
initially published  in  2001  and  updated  in  2008  and  2010,  has  been  very  successful  in  dissemi-
nating information  and  evidence,  as  well  as  providing  a  classification  of  severity  and  proposing
a systemized  treatment  protocol.  In  order  to  include  the  participation  of  other  medical  profes-
sionals in  the  treatment  of  allergic  rhinitis,  it  is  important  to  develop  algorithms  that  accurately
indicate what  should  and  can  be  done  regionally.
Objective:  To  update  the  III  Brazilian  Consensus  on  Rhinitis  --  2012,  with  the  creation  of  an
algorithm  for  allergic  rhinitis  management.
Methods:  We  invited  24  experts  nominated  by  the  Brazilian  Association  of  Allergy  and  Immunol-
ogy, Brazilian  Association  of  Otorhinolaryngology  and  Head  and  Neck  Surgery  and  Brazilian
Society of  Pediatrics  to  update  the  2012  document.
Results:  The  update  of  the  last  Brazilian  Consensus  on  Rhinitis  incorporated  and  adapted  the
relevant information  published  in  all  ‘‘Allergic  Rhinitis  and  its  Impact  on  Asthma’’  Initiative
documents  to  the  Brazilian  scenario,  bringing  new  concepts  such  as  local  allergic  rhinitis,  new
drugs and  treatment  evaluation  methods.
Conclusion:  A  flowchart  for  allergic  rhinitis  treatment  has  been  proposed.
© 2017  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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IV  Consenso  Brasileiro  sobre  Rinite  --  atualizac¸ão  em  rinite  alérgica
Resumo
Introduc¸ão:  As  diretrizes  sobre  rinite  alérgica  visam  atualizar  os  conhecimentos  sobre  a  doenc¸a
e os  cuidados  para  com  esses  pacientes.  A  iniciativa  designada  ‘‘Rinite  Alérgica  e  seu  Impacto
na Asma’’,  cujo  relatório  inicial  foi  publicado  em  2001  e  atualizada  em  2008  e  2010,  tem  sido
muito bem  sucedida  na  disseminac¸ão  de  informac¸ões  e  evidências,  bem  como  na  formulac¸ão
da classificac¸ão  de  gravidade  e  proposta  de  sistematizac¸ão  do  tratamento.  Entretanto,  visando
a participac¸ão  de  outros  profissionais  médicos  no  atendimento  da  rinite  alérgica,  é  impor-
tante o  desenvolvimento  de  algoritmos  que  indiquem  com  precisão  o  que  deve  e  pode  ser  feito
regionalmente.
Objetivo:  Atualizar  o  III  Consenso  Brasileiro  sobre  Rinites-2012,  com  elaborac¸ão  de  algoritmo
para conduta  da  rinite  alérgica.
Método:  Foram  convidados  24  especialistas  indicados  pelas  Associac¸ão  Brasileira  de  Alergia  e
Imunologia,  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial  e  Sociedade
Brasileira  de  Pediatria  para  atualizac¸ão  do  documento  de  2012.
Resultados:  A  atualizac¸ão  do  último  Consenso  Brasileiro  sobre  Rinites,  incorporou  e  adaptou
para a  realidade  brasileira  as  informac¸ões  relevantes  publicadas  em  todos  os  documentos  da
Iniciativa  ‘‘Rinite  Alérgica  e  seu  Impacto  na  Asma’’,  trazendo  novos  conceitos  como  a  rinite
alérgica local,  novos  medicamentos  e  métodos  de  avaliac¸ão  de  tratamento.
Conclusão:  Proposto  um  fluxograma  de  tratamento  para  a  rinite  alérgica.
© 2017  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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Importance of guidelines for allergic rhinitis
management
Guidelines  for  the  treatment  of  allergic  rhinitis  (AR)  devel-
oped  over  the  past  20  years  have  better  elucidated  the
care  for  patients  with  the  disease.  An  expert  workshop
conducted  by  the  World  Health  Organization  (WHO)  in
December  1999  led  to  an  initiative  called  ‘‘Allergic  Rhini-
tis  and  its  Impact  on  Asthma’’  (ARIA),  of  which  initial
evidence-based  report  had  nearly  3000  references  and  was
published  in  2001.1 An  update  of  the  ARIA  report  was
published  in  2008,  based  on  new  evidence.2 This  new
report  resulted  from  an  ongoing  review  of  the  literature
on  previously  uncovered  aspects,  such  as:  Complementary
and  Alternative  Medicine,  sports,  update  on  the  associ-
ations  between  rhinitis  and  asthma,  and  prevention  and
treatment.
However,  it  is  necessary  to  have  clear  information  on
the  guidelines  to  facilitate  their  understanding  and  accep-
tance.  The  ARIA  Guide  was  the  first  guideline  for  chronic
respiratory  disease  to  use  the  classification  of  the  Grading
of  Recommendations,  Assessment,  Development  and  Evalu-
ations  (GRADE)  system,  an  advanced  method  that  has  been
adopted  by  the  WHO.  A  new  ARIA  review  was  published  in
2010,3 ten  years  after  the  publication  of  the  first  report  of
the  ARIA-WHO  workshop.  The  ARIA  Initiative  has  been  very
successful  in  disseminating  information  and  evidence,  as
well  as  providing  a  classification  of  severity  and  proposing  a
systemized  treatment  protocol.  However,  this  is  insufficient
to  guide  new  practices,  especially  when  they  involve  the
participation  of  family  physicians,  pediatricians,  and  other
health  professionals.  It  is  necessary  to  develop  algorithms
that  accurately  indicate  what  should  and  can  be  done  for  a
specific  case  in  your  region.  A  recent  publication  of  experts
from  the  ARIA  Initiative  proposes  a  decision-making  algo-
rithm  in  clinical  practice  for  AR  control  in  adolescents  and
adults.4,5
The  update  of  the  Brazilian  Consensus  on  Rhinitis  --  2017
incorporates  and  adapts  to  the  Brazilian  reality  the  relevant
information  published  in  all  ARIA  Initiative  documents,  as
was  done  in  previous  versions  of  the  Brazilian  document,6,7
that  were  always  created  by  representatives  of  the  Brazilian
Association  of  Allergy  and  Immunology  (Associac¸ão  Brasileira
de  Alergia  e  Imunologia) and  the  Brazilian  Association  of
Otorhinolaryngology  and  Head  and  Neck  Surgery  (Associac¸ão
Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial)
and  the  Brazilian  Society  of  Pediatrics  (Sociedade  Brasileira
de  Pediatria).
The  main  updates  made  in  the  base  document  of  20127
were  thus  established.
Definition of rhinitis
Rhinitis  is  an  inflammation  and/or  dysfunction  of  the  nasal
mucosa  characterized  by  some  of  these  nasal  symptoms:
nasal  obstruction,  anterior  and  posterior  rhinorrhea,  sneez-
ing,  nasal  pruritus  and  hyposmia.  Symptoms  usually  occur
for  two  or  more  consecutive  days  for  more  than  1  h  on  most
days.8
T
o
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hinitis classification
lassification  reflects  the  criteria  utilized  (clinical  data,
requency  and  intensity  of  symptoms,  nasal  cytology,  etio-
ogical  factors,  and  phenotypes  [clinical,  temporal  pattern,
everity,  duration,  control,  treatment  response,  and  pres-
nce  of  comorbidities]).9
In  a  recent  document,  the  European  Academy  of  Allergy
nd  Immunology  proposed  a  classification  of  chronic  rhini-
is  based  on  the  main  etiological  agent.  It  consists  of
 subgroups:  (1)  infectious  rhinitis,  (2)  allergic  rhinitis,
3)  non-infectious,  non-allergic  rhinitis,  and  (4)  mixed  rhini-
is.  Infectious  rhinitis  is  acute  and  self-limiting,  and  is
sually  caused  by  viruses,  and  less  frequently  by  bacte-
ia.  Allergic  rhinitis  is  the  most  common  form  and  is
nduced  by  inhalation  of  allergens  in  sensitized  individuals.
on-infectious,  non-allergic  rhinitis  represents  a  heteroge-
eous  group  of  patients  with  no  signs  of  infection  and  no
ystemic  signs  of  allergic  inflammation;  examples  include
rug-induced  rhinitis,  rhinitis  of  the  elderly,  hormonal  rhini-
is,  gestational  rhinitis,  occupational  non-allergic  rhinitis,
ustatory  rhinitis,  and  idiopathic  rhinitis.  Mixed  rhinitis
ccurs  in  patients  with  chronic  rhinitis  who  have  more  than
ne  etiological  agent,  known  or  unknown.10
Another  recent  concept  is  that  of  the  endotype  that
ims  to  identify  the  underlying  mechanisms  involved  in  the
enesis  of  the  disease,  thus  allowing  targeted  and  more
ccurate  treatment  for  each  patient.9,10 These  endotypes
re  complex  and  secondary  to  cell  processes  (eosinophils,
eutrophils  and  inflammatory  mediators  caused  by  them),
olecular  (total  and  specific  serum  IgE,  inflammatory
ytokines  and  chemokines)  and  structural  damage  of  the
asal  mucosa.9,10 To  date,  four  rhinitis  endotypes  have  been
dentified:  (a)  with  type  2  immune  response;  (b)  with  type  1
mmune  response;  (c)  neurogenic  rhinitis;  (d)  epithelial  dys-
unction  (9).  A  better  characterized  rhinitis  can  receive  an
ndividualized  and  more  specific  treatment,  with  a  greater
hance  of  success.
llergic rhinitis
he  classification  of  the  ARIA  guide,  based  on  symptom
requency  and  intensity,  was  maintained  due  to  its  great
cceptance  in  the  Brazilian  medical  scenario.1
revalence
s  observed  in  several  parts  of  the  world,  the  International
tudy  of  Asthma  and  Allergic  Diseases  in  Childhood  carried
ut  in  several  Brazilian  locations,  has  shown  an  increase  in
he  prevalence  of  nasal  symptoms  among  children  and  ado-
escents  in  the  last  year,  reaching  37.2%  (oscillating  between
6.3%  and  49.9%)  and  16.2%  (ranging  from  15.4%  to  27.9%)
or  allergic  rhinoconjunctivitis.11
linical  picturehe  clinical  picture  remains  important  for  the  diagnosis
f  allergic  rhinitis.  In  addition  to  the  characteristic  symp-
oms  (sneezing,  itching,  rhinorrhea  and  nasal  obstruction)
6  Sakano  E  et  al.
Table  1  Triggering  factors  for  respiratory  allergies.16
Aeroallergens
House  dust  mites  Dermatophagoides  pteronyssinus,  Dermatophagoides  farinae,  Blomia  tropicalis
Cockroaches  Blattella  germanica,  Periplaneta  americana
Fungi Aspergillus  sp,  Cladosporium  sp,  Alternaria  sp,  Penicillium  notatum
Pets Cats,  dogs,  rabbits,  horses  and  rodents  (hamster,  guinea  pig,  domestic  ferret,  mice)
Pollens Grasses  -- Lolium  multiflorum  (ryegrass),  Phleum  pratense
Occupational  Wheat,  wood  dust,  detergents,  latex
Pollutants
Intra-domiciliary  Cigarette  smoke,  particulate  matter  (PM  10)  and  nitrogen  dioxide  (NO  2)  derived  from  cooking
gas or  wood  stove  combustion
Extra-domiciliary  Ozone,  NOx  and  sulfur  dioxide
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(Irritant  agents  Strong  odors,  perfumes,  air  con
btaining  a  personal  and  comprehensive  allergic  history  is
rucial,  as  well  as  identifying  any  triggering  factors.12
riggering  factors
ational  studies  have  reinforced  the  involvement  of  house
ust  mites  as  the  main  etiological  agents  of  allergic  rhini-
is,  followed  by  cockroach,  pet  epithelium  and,  more  rarely,
ungal  allergens.13,14 In  the  southern  region  of  the  country,
ollen  is  an  important  factor  in  the  sensitization  of  adults
nd  children.15 The  role  of  mucosal  irritants  is  reinforced,
ith  special  emphasis  on  pollutants  and  irritants  (Table  1).16
Foods  rarely  trigger  respiratory  symptoms  alone.  Most
ften  they  occur  as  manifestations  associated  with  more
evere  conditions,  such  as  anaphylaxis.17
athophysiology
ellular  and  molecular  mechanisms  involved  in  the  allergic
eaction  and  responsible  for  allergic  inflammation  are  shown
o  facilitate  the  understanding  of  the  different  proposed
ndotypes  of  rhinitis.9
iagnostic  resources
ccording  to  the  purpose  of  evaluation  they  are  divided
nto:  (a)  etiological  diagnosis,  (b)  nasal  cavity  assessment,
c)  imaging  assessment  and  (d)  complementary  assessment.
a)  Etiological  diagnosis
The  most  important  subsidiary  exams  in  the  etiological
diagnosis  of  allergic  rhinitis,  both  for  specificity  and  sen-
sitivity,  are  the  skin  prick  test  (SPT)  and  the  evaluation
of  serum  levels  of  allergen-specific  IgE.  The  diagnosis  of
allergy  and  the  identification  of  the  most  relevant  aller-
gens  in  each  case  are  important  for  targeted  preventive
interventions,  such  as  environmental  control,  pharmaco-
logical  treatment  options  and,  finally,  the  possibility  of
specific  immunotherapy  with  allergens.The  SPTs  with  aeroallergens  are  the  most  commonly
used  tests  in  the  diagnosis  of  respiratory  allergy  and
portray  IgE-mediated  allergic  reactions.  They  should
preferably  be  performed  with  standardized  allergens,ing,  cleaning  products
chosen  according  to  the  clinical  relevance  of  the
patient’s  history,  age,  profession,  environment,  and
regional  distribution  of  allergens;  they  should  be  per-
formed  under  direct  supervision  of  an  appropriately
trained  physician  to  avoid  false-positive  and  false-
negative  results  and  potential  systemic  reactions.18 The
reaction  intensity  is  generally  reduced  in  the  extremes  of
life  and  in  the  presence  of  extensive  eczema  or  dermo-
graphism.  The  use  of  oral  antihistamines  and  of  topical
corticosteroids  in  the  preceding  7  days  are  contraindica-
tions  for  the  test.18
Although  high  levels  of  total  serum  IgE  are  recognized
by  some  authors  as  synonymous  with  allergic  disease,
they  can  also  be  detected  in  different  diseases  such
as  HIV  infection,  allergic  pulmonary  aspergillosis,  aller-
gic  fungal  sinusitis,  lymphomas,  tuberculosis,  parasitic
diseases  with  a  pulmonary  cycle,  and  others.  Thus,  its
significance  in  the  diagnosis  of  allergies  is  limited.  Simi-
lar  to  the  SPT,  total  serum  IgE  levels  are  low  in  the  first
years  of  life.19
On  the  other  hand,  the  presence  of  serum  specific  IgE
to  a  particular  allergen  is  a  strong  indicator  of  aller-
gic  sensitization,  but  should  not  be  considered  in  the
absence  of  allergic  symptoms.20,21 It  has  a  sensitivity  and
specificity  similar  to  those  of  SPT,  but  it  is  more  expen-
sive  and  requires  a  venepuncture,  specialized  laboratory
techniques  and  takes  longer  to  obtain  the  result.  How-
ever,  it  is  not  affected  by  medications  and  skin  conditions
and  does  not  harbor  the  risk  of  severe  allergic  reactions.
It  can  be  used  to  evaluate  a  greater  number  of  allergens,
has  better  reproducibility  and  is  not  affected  by  the  test
technique.20
More  recently,  the  acquisition  of  Component  Resolved
Diagnostic  (CRD)  allowed  the  determination  of  specific
IgE  to  multiple  allergens  (recombinant  or  not)  using
the  microarray  technique  (e.g., Immuno-solid-phase
allergen  chip  (ISAC)  assay)  allowing  greater  diagnostic
precision  and  the  possibility  to  discriminate  cross-
sensitization  co-sensitization  by  different  allergens  that
have  the  same  protein  in  their  composition.21,22In  Brazil,  ImmunoCap-ISAC  (ThermoFisher  Scientific),  a
multiple  platform  that  identifies  112  natural  or  recombi-
nant  components  from  51  allergenic  sources  is  available.
Its  high  cost  still  limits  its  use  to  very  special  cases.
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fIV  Brazilian  Consensus  on  Rhinitis  --  an  update  on  allergic  rh
Although  nasal  provocation  tests  (NPTs)  are  more  com-
monly  used  in  the  research  setting,  they  have  shown  to
be  useful  in  allergic  rhinitis  diagnosis,  including  local
allergic  rhinitis,  and  non-allergic  rhinitis.23--25 They  are
useful  in  the  diagnosis  of  occupational  rhinitis,  aiming
to  identify  and  quantify  the  clinical  relevance  of  inhaled
allergens  or  occupational  irritants.23,24 NPTs  should  be
performed  by  specialized  physicians  at  appropriate  sites
and  using  standardized  allergen  extracts;  the  assess-
ment  of  nasal  response  may  be  performed  by  symptom
score,  but  the  use  of  the  objective  monitoring  method  is
recommended.23,24
b)  Nasal  cavity  assessment
Other  examinations  such  as  nasal  cytology,  bacte-
rioscopy,  and  culture  of  airway  secretions,  olfaction
evaluation,  nasal  permeability  (by  acoustic  rhinome-
try,  rhinomanometry,  or  peak  nasal  flow)  are  used  less
frequently.12
c)  Imaging  assessment
The  plain  rhinopharynx  radiograph  is  useful  for  the
diagnosis  of  nasal  obstruction  by  pharyngeal  tonsil
hypertrophy  (adenoid)  or  other  rhinopharyngeal  tumor
processes.  The  paranasal  sinuses  radiographs  (Waters’
and  Caldwell’s  Views)  have  no  role  in  the  diagnosis  of
allergic  rhinitis.26
Computed  tomography  and  magnetic  resonance  imag-
ing  of  the  paranasal  sinuses  may  be  necessary  in  the
evaluation  of  chronic  inflammatory  and  infectious  sinus
conditions,  complications  of  acute  infectious  condi-
tions,  and  evaluation  of  benign  and  malignant  tumor
processes.26
d)  Complementary  assessment
It is  known  that  allergic  rhinitis  has  a  high  impact  on
the  lives  of  patients  and  their  families.  Recently,  self-
administered  questionnaires  have  been  created  to  allow
a  broader  evaluation  of  patients  and  allow  a  more  per-
sonalized  and  comprehensive  therapeutic  approach.  The
most  important  are  those  that  evaluate  sleep  disorders
and  those  that  assess  quality  of  life.
Sleep-related  disorders  (SRDs)  are  associated  with
environmental,  social,  cultural,  biological,  family  and
emotional  factors  and  are  generally  underreported  and
often  not  considered  and  investigated.27,28 Polysomno-
graphy  is  the  gold  standard  for  the  diagnosis  of  SRDs
and  is  an  objective  evaluation;  however,  it  is  expensive
and  difficult  to  perform,  which  limits  its  use  in  popula-
tion  studies.  Sleep  diaries  are  inexpensive,  but  require
time  and  compliance  to  complete,  and  are  difficult  to
interpret.28
Recently,  written  questionnaires  have  been  developed
to  evaluate  SRDs  in  different  age  groups.  They  are  self-
administered  and  easy  to  apply,  as  well  as  low-cost
and  useful  for  use  in  large  studies.29,30 One  example
is  the  Children’s  Sleep  Habits  Questionnaire  (CSHQ).31
A  recent  study  documented  a  significantly  higher  CSHQ
score  in  children  with  asthma  and/or  rhinitis  compared
to  healthy  children,  especially  those  with  poorly  con-
trolled  disease.32Other  tools  that  have  been  increasingly  used  in  the
follow-up  of  patients  with  allergic  rhinitis  are  the  Health-
Related  Quality  of  Life  (HRQL)  questionnaires  that  allow
a  broader  assessment  of  how  the  disease  interferes  with
r
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the  patient’s  daily  life.  They  are  short,  self-applied,
easy  to  understand  and  inexpensive.33 Some  examples  of
these  questionnaires  are  the  Rhinoconjunctivitis  Quality
of  Life  Questionnaire  (RQLQ),34 the  Mini  Rhinoconjunc-
tivitis  Quality  of  Life  Questionnaire  (MiniRQLQ)35 and  the
Pediatric  Rhinoconjunctivitis  Quality  of  Life  Question-
naire  (PRQLQ).36
omorbidities
he  main  comorbidities  associated  with  allergic  rhinitis
re  asthma,  allergic  conjunctivitis,  acute  and  chronic  rhi-
osinusitis,  otitis  media  with  effusion  and  changes  in  the
raniofacial  development  of  oral  breathers  in  children,  as
ell  as  obstructive  sleep  apnea  and  hypopnea,  both  in  chil-
ren  and  in  adults.12
reatment
he  treatment  of  the  patient  with  allergic  rhinitis  includes
on-pharmacological  and  pharmacological  measures.  Non-
harmacological  measures  aim  to  reduce  the  patient’s
xposure  to  irritants  and/or  agents  to  which  they  are  sen-
itized.  Although  there  is  debate  about  the  effects  of
hese  environmental  control  measures  on  the  control  of
espiratory  allergies,  they  have  been  defended  by  several
esearchers.37 Table  2  lists  the  main  measures  to  be  taken
or  effective  environmental  control.16
For  pharmacological  measures,  we  highlight  the  differ-
nt  classes  of  drugs  commonly  used  in  the  therapeutic
pproach  of  patients  with  allergic  rhinitis:  H1  antihistamines
lone  (anti-H1,  systemic  or  nasal  topical),  deconges-
ants  (systemic,  nasal  topical),  corticosteroids  (systemic,
asal  topical),  disodium  cromoglycate,  and  leukotriene
eceptor  antagonists.  In  addition  to  these,  saline  solu-
ion,  allergen-specific  immunotherapy  and,  more  recently,
mmunobiological  agents  have  constituted  the  therapeutic
rsenal  of  patients  with  allergic  rhinitis.12
Anti-H1  agents  are  considered  first-line  drugs  for  the
reatment  of  AR,  especially  the  second  generation  or  non-
lassic  drugs.2,3,7 As  they  act  on  the  histamine  H1  receptor,
hey  effectively  relieve  the  symptoms  of  the  immediate
hase  of  AR,  such  as  nasal  pruritus,  sneezing,  rhinorrhea
nd  associated  ocular  symptoms,  and  improve  the  nasal
bstruction  characteristic  of  the  late  phase  of  the  disease.38
ecause  they  are  less  lipophilic  and  have  low  passage
hrough  the  blood-brain  barrier,  they  bind  poorly  to  brain
1  receptors  and,  therefore,  cause  fewer  adverse  effects
n  the  central  nervous  system,  such  as  sedation.39
Second-generation  anti-H1s  have  a  rapid  onset  of  action;
he  duration  of  use  of  these  medications  varies  from  1  to
 weeks,  but  they  may  be  used  for  prolonged  periods  of
ime  in  moderate  to  severe  and  persistent  cases.  Due  to
heir  excellent  safety  profile  and  therapeutic  advantages  in
he  treatment  of  allergic  rhinitis,  second-generation  anti-H1
hould  always  be  prescribed,  rather  than  older  compounds
or  all  age  groups.40--42In  addition  to  oral  formulations,  antihistamines  are  cur-
ently  available  for  nasal  and  topical  ophthalmological  use.
asal  topical  anti-H1  have  similar  efficacy  to  the  oral  com-
ounds,  and  have  as  a  therapeutic  advantage  a  faster  onset
8  Sakano  E  et  al.
Table  2  Environmental  control  measures.16
-- The bedroom should be preferably well ventilated and sunny. Avoid pillows and mattresses made of kapok fibers or feathers and
prefer those made of foam, artificial fibers or latex, wherever possible covered by plastic material (vinyl) or mite-impermeable
covers. The bed frame should be cleaned twice a month. Bedding and blankets should be changed and washed regularly with
detergent and at high temperatures (>55 ◦C) and dried in the sun or with hot air. If possible, the mattress surface should be vacuumed
using a powerful domestic vacuum cleaner model.
-- Avoid rugs, carpets, curtains and cushions. Give preference to washable floors (ceramic, vinyl and wood) and venetian blinds or
shutters instead of curtains, made of material that can be cleaned with a damp cloth. If the carpets or rugs are very heavy and
difficult to remove, they should be vacuumed twice a week, if possible, after being allowed to ventilate.
-- Beds and cribs should not be placed next to the wall. If that is not possible, place it next to the wall with no marks of humidity or
next to the sunniest one.
-- Avoid stuffed animals, book shelves, magazines, cardboard boxes or any other place where dust mite colonies can be formed in the
bedroom. Replace them with fabric toys, so they can be washed frequently.
-- Identify and eliminate mold and moisture, especially in the bedroom, reducing humidity to less than 50%. Periodically check the
humid areas of your home, such as bathroom (plastic shower curtains, under the sinks, etc.). A diluted bleach solution can be applied
to the moldy places until its final resolution, even though they are respiratory irritants. It is essential to investigate other sources of
exposure to fungi outside the home (day care, school and workplaces).
-- Avoid using ordinary brooms, dusters, and vacuum cleaners. Use a damp cloth daily to clean the house or use vacuum cleaners with
special filters twice a week. Remove the allergic patient from the environment while cleaning.
-- Environments that have been closed for prolonged periods (beach or country house) should be ventilated and cleaned at least 24 h
prior to the arrival of individuals with respiratory allergy.
-- Avoid the presence of pet animals and birds, especially in the patient’s bedroom and bed (safe environment). Keep the bedroom
door always closed. If it is impossible, restrict the animal to a single area of the house and use HEPA filters in the patient’s room.
Preferably, pets for allergic children should be fish and turtles.
-- Avoid exposure to mouse and rat allergens, with professional intervention integrated with house cleaning measures; including the
placement of traps, sealing of holes and cracks that may  serve as entry points and the use of rodenticide in cases of large infestations.
-- Inspection is an important step for cockroach extermination. Avoid insecticides and cleaning products with strong odors; prefer
using the bait method. Exterminating cockroaches and rodents may be necessary.
-- Remove the garbage and keep food in closed packages, as these attract rodents. Do not store garbage indoors.
-- Give preference to soap paste and powder versions for bathroom and kitchen cleaning. Avoid talcum powder, perfumes,
deodorants, especially in spray.
-- Do not smoke or allow smoking inside your home or car. Prenatal, perinatal and postnatal smoking is associated with future
respiratory problems in the offspring.
-- Avoid extremely hot baths and sudden temperature fluctuations. The ideal temperature of the water is body temperature.
-- Prefer the outdoor life. Sports can and should be practiced, avoiding days with high exposure to pollen or pollutants in certain
geographic areas.
-- Patients allergic to pollen are advised to keep the house and car windows closed during the day, opening them at night (lower
pollen count). House and car ventilation systems should be equipped with special pollen filters. Protective masks and safety glasses
are useful. Pollen can be transported indoors on clothing and pets. Avoid leaving clothes to dry in the open air; if possible, use an
electric dryer.
-- Avoid outdoor activities during periods of high pollen counts, between 5 and 10 o’clock in the morning and on hot, windy, and dry
days.
-- Keep air conditioner filters clean. If possible, clean them monthly. Avoid exposure to very low ambient temperature and sudden
temperature fluctuations. Remember that the conditioned air is dry and can be irritating.
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tIV  Brazilian  Consensus  on  Rhinitis  --  an  update  on  allergic  rh
of  action  and  greater  effectiveness  in  controlling  nasal
obstruction.43--45
Nasal  decongestants  are  adrenergic  or  adrenomimetic
stimulants  with  a  principal  action  of  vasoconstriction,  result-
ing  in  rapid  relief  of  nasal  obstruction  in  allergic  rhinitis.46
They  are  divided  into  two  groups:  oral  and  nasal  topi-
cal  use.  Pseudoephedrine  is  the  most  commonly  used  oral
decongestant,  followed  by  phenylephrine.  In  Brazil,  these
are  only  available  in  combination  with  an  anti-H1  agent.
Pseudoephedrine  should  be  used  with  caution  due  to  its  psy-
chotropic  action  and  potential  cardiovascular  side  effects.
It  is  not  recommended  for  patients  younger  than  4  years
of  age  because  of  the  increased  risk  of  toxicity,  and  pro-
longed  release  formulations  at  doses  of  120  mg  are  not
recommended  for  children  under  12  years  of  age.46,47 Top-
ical  nasal  decongestants  should  be  used  at  maximum  for
up  to  5--7  days,  as  prolonged  use  increases  the  risk  of
drug-resistant  rhinitis,  very  often  a  difficult  problem  to
resolve.  Furthermore,  they  can  cause  important  cardio-
vascular  effects,  as  well  as  affect  the  central  nervous
system  (imidazole  derivatives);  they  are  contraindicated
in  children  below  six  years  of  age.  They  should  also  be
avoided  in  the  elderly,  due  to  the  higher  incidence  of
hypertension  and  urinary  retention  resulting  in  this  age
group.46
The  combination  of  oxymetazoline  and  mometasone
furoate  for  nasal  topical  use  achieved  a  rapid  onset  of
action,  better  efficacy  on  nasal  obstruction,  and  a  reduction
in  polyp  size  in  patients  with  seasonal  allergic  rhinitis  and
nasal  polyposis,  compared  to  the  two  drugs  administered
separately.48,49
Corticosteroids,  which  are  potent  anti-inflammatory
agents,  have  been  widely  used  in  the  treatment  of  sev-
eral  diseases,  including  allergies.  In  patients  with  allergic
rhinitis,  systemic  corticosteroids  are  reserved  for  patients
with  severe  exacerbations  or  severe  forms  of  allergic  rhini-
tis,  and  always  for  a  short  period  of  time  (5--7  days)  to
prevent  adverse  effects  resulting  from  prolonged  use.2,12
However,  parenteral  administration  of  prolonged  action  cor-
ticosteroids  (known  as  depot),)  is  contraindicated  in  the
management  of  rhinitis,  especially  in  children  and  the
elderly,  due  to  adverse  systemic  effects.12 A  recent  study
evaluated  the  action  of  the  combination  of  Desloratadine
(0.5  mg/mL)  and  prednisolone  (4  mg/mL)  for  7  days  in  chil-
dren  (2--12  years)  with  a  severe  acute  crisis  of  allergic
rhinitis  and  documented  significant  symptom  control  in  the
first  24  h  accompanied  by  a  lower  incidence  of  adverse
events,  especially  drowsiness.50
Nasal  corticosteroids  (NCs)  for  topical  use  have  a  broader
safety  profile,  that  allows  them  to  be  used  for  longer
periods  of  time  and  are  the  anti-inflammatory  treatment
of  choice  recommended  by  most  specialists  treating  aller-
gic  rhinitis  (from  several  medical  societies1--3,8,12,51).  Nasal
corticosteroids  for  topical  use  have  also  been  shown  to  be
effective  in  controlling  occupational,  gestational,  and  idio-
pathic  rhinitis.51
NCs  improve  nasal  congestion,  olfactory  alterations,  rhi-
norrhea,  sneezing,  nasal  pruritus  and  associated  ocular
symptoms  secondary  to  a  possible  action  on  the  naso-ocular
reflex  (allergic  rhinoconjunctivitis).  Their  use  results  in  the
improvement  of  quality  of  life,  quality  of  sleep  and  day-
time  concentration.  Treatment  with  NCs  also  reduces  the
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isk  of  complications  such  as  rhinosinusitis,  secretory  otitis
nd  asthma.1,2,12
In  Brazil  the  available  NC  formulations  are  beclometha-
one  dipropionate  (BDP),  budesonide  (BUD),  fluticasone
ropionate  (FP),  mometasone  furoate  (MF),  fluticasone
uroate  (FF)  and  ciclesonide  (CIC).  The  NCs  approved  for  use
n  individuals  older  than  two  years  of  age  are  MF  and  FF;  for
hose  older  than  4  years  of  age,  they  are  BUD  and  FP,  while
DP  and  CIC  are  reserved  for  those  older  than  6  years.12
C  onset  of  action  occurs  7--12  h  after  administration,  but
atients  should  be  advised  that  the  final  therapeutic  benefit
ay  take  up  to  14  days.12,51 Although  all  of  the  agents  have
n  anti-inflammatory  action,  they  differ  in  their  pharmaco-
ynamic  and  pharmacokinetic  characteristics,  which  gives
hem  different  safety  profiles.51
Studies  show  that  the  therapeutic  effect  of  NCs  depends
ot  only  on  the  effectiveness  of  the  active  substance,  but
lso  on  the  deposition  of  the  product  in  the  nasal  cavity
spray  or  aerosol),51,52 their  affinity  for  the  glucocorticoid
eceptor,  and  the  concentration--time  association  at  the
ite  of  action  and  lipophilicity,  which  are  important  fac-
ors  for  both  the  therapeutic  effect  and  the  potential  to
each  the  systemic  circulation  (systemic  availability)  for  its
limination.51,52 It  is  believed  that  the  ideal  NCs  should  have
igh  lipophilicity,  low  systemic  availability  and  high  systemic
learance.52,53
The  adverse  effects  of  NC  are,  for  the  most  part,  depend-
nt  on  serum  availability,  which  is  decreased  by  the  ability  of
he  drug  to  bind  to  plasma  proteins.  The  new  generation  of
Cs  exhibits  high  affinity  for  plasma  protein  binding  which
ffects  its  systemic  bioavailability:  FF,  FM  and  CIC  bind  in
9%;  FP  in  90%,  BUD  in  88%  and  BDP  in  87%.53,54
The  main  adverse  effects  related  to  the  use  of  NCs  are
ocal  (irritation,  bleeding,  septal  perforation)  and  can  be
bserved  with  any  of  the  drugs  used  and  are  dependent  on
he  dosage  and  the  technique  of  administration.  Systemic
dverse  effects  (interference  with  the  hypothalamic-
ituitary-adrenal  axis,  ocular  effects,  effects  on  growth,
one  resorption  and  skin  effects),  can  vary  according  to  the
atient’s  age,  dosage  and  drug  pharmacokinetics.53,54
Although  indicated  as  safe,  even  on  a small  scale,  all  NCs
re  absorbed  systemically  in  part  and  may  exhibit  adverse
ffects.  The  effects  of  NCs  in  children  and  in  pregnant
omen  are  similar  to  those  observed  in  adult  patients.54
owever,  the  use  of  NCs  in  pregnant  women  requires  greater
onsideration,  since  there  is  always  concern  about  embryo-
enesis.  BUD  is  the  only  NC  that  falls  into  category  B  for
se  in  pregnancy,  mandating  a  prescription  at  the  smallest
ossible  dose  and  duration.55
The  combination  of  anti-H1  (azelastine  hydrochloride)
nd  NC  (fluticasone  propionate)  for  topical  use  in  a  single
ispenser  was  initially  recommended  only  for  patients  over
2  years  of  age  who  had  persistent  moderate  or  severe  symp-
oms  not  controlled  by  an  anti-H1  and/or  NC.55--58 It  has  now
een  shown  to  be  effective  and  safe  in  children  aged  four
ears  and  older.59,60
Studies  in  patients  with  allergic  rhinitis  have  compared
reatments  with  the  combination  of  the  two  drugs  to  the
rugs  administered  separately  and  found  that  the  combina-
ion  was  more  effective  in  the  control  of  these  patients,55--60
nd  there  was  no  loss  of  effectiveness  even  when  they  were
dministered  for  prolonged  periods  of  time.61 The  incidence
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f  adverse  events  has  been  similar  to  that  observed  with
atients  treated  with  placebo.  To  date,  there  are  insuf-
cient  data  on  their  safety  in  pregnant  or  breastfeeding
omen.55,61
Disodium  cromoglycate  has  a  stabilizing  action  on  the
embrane  of  mast  cells  and,  consequently,  prevents  the
elease  of  their  chemical  mediators  during  the  allergic  reac-
ion.  They  are  superior  to  placebo,  but  much  less  effective
ompared  to  anti-H1  and  NCs  in  the  control  of  rhinorrhea,
neezing  and  nasal  pruritus,  in  addition  to  having  little  effect
n  nasal  obstruction.2,62 The  drug  has  an  excellent  safety
rofile,  making  it  an  acceptable  therapeutic  alternative  in
nfants,  an  age  group  for  which  NCs  are  not  approved.2,62
ue  to  its  short  half-life,  it  is  administered  4  to  6  times  a
ay,  which  makes  treatment  adherence  difficult.
Montelukast  sodium  (MS)  is  the  only  compound  repre-
entative  of  leukotriene  receptor  antagonists  available  in
razil.  It  is  superior  to  placebo  in  symptom  control  and  qual-
ty  of  life  improvement  of  patients  with  allergic  rhinitis.63--65
lthough  MS  is  not  the  first  choice  for  the  treatment  of
atients  with  allergic  rhinitis,  it  has  been  suggested  as
 therapeutic  alternative  for  patients  with  concomitant
sthma  and  allergic  rhinitis66 and  in  those  with  difficulty
dhering  to  treatment  regimens  using  topical  nasal  med-
cation.  Additionally,  they  can  be  considered  in  cases  of
hronic  rhinosinusitis  with  nasal  polyposis,  and  in  aspirin-
xacerbated  respiratory  disease  (AERD).
Recently  an  association  between  an  anti-H1  (levoceti-
izine  5  mg  +  montelucaste  de  sódio  10  mg)  has  been  made
vailable  for  individuals  older  than  18  years.67 Studies  in
dults  have  shown  that  the  combined  therapy  is  superior  to
oth  medications  when  given  alone.68--70
Allergen-specific  immunotherapy  (SIT)  remains  the
nly  treatment  that  can  modify  the  allergic  disease.71
dditionally,  it  provides  long-lasting  benefits  after  its
iscontinuation,72 prevents  the  progression  of  disease,
ncluding  the  development  of  asthma,73,74 as  well  as  the
evelopment  of  new  sensitizations.75--77
SIT  is  recommended  for  the  treatment  of  adults  and  chil-
ren  (>5  years)  with  intermittent  moderate/severe  allergic
hinitis  and  in  all  its  persistent  forms,77 always  by  a spe-
ialist  in  allergology.  The  indication  of  SIT  must  be  based
n  the  evidence  of  specific  allergen  sensitization  by  in  vivo
r  in  vitro  methods,  the  relevance  of  the  allergen  (s)  for
ymptom  onset,  the  impossibility  of  avoiding  exposure  to
he  allergen  (s)  and  the  availability  of  standardized  and
onfirmed  effective  allergen  extract.12,78 It  is  a  long-term
herapeutic  procedure.
The  following  are  absolute  contraindications  to  SIT:
ncontrolled  asthma,  active  autoimmune  disease,  malig-
ant  neoplasm,  children  under  two  years  old,  and  patients
ith  human  immunodeficiency  virus  (HIV)  infection.  The  fol-
owing  are  relative  contraindications:  partially  controlled
sthma,  autoimmune  disease  in  remission,  use  of  beta-
lockers,  cardiovascular  diseases,  children  between  2  and  5
ears  of  age,  HIV  infection  (classification  A  and  B,  CD4  >  200
ells/mm3),  chronic  infections,  immunodeficiencies  and  use
f  immunosuppressants.79Nasal  lavage  with  saline  solution  has  been  used  as  an
djuvant  in  the  treatment  of  acute  and  chronic  nasal  condi-
ions.  As  it  is  an  inexpensive,  practical  and  well-tolerated
ethod,  it  became  very  widespread.  The  use  of  saline
c
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olution  facilitates  the  removal  of  secretions,  thus  promot-
ng  symptomatic  relief  to  patients.51 In  the  specific  case
f  inflammatory  and  allergic  rhinitis,  nasal  lavage  also  pro-
otes  the  removal  of  inflammatory  mediators  present  in  the
asal  mucus,  therefore  improving  the  clinical  picture.51 Iso-
onic  saline  should  be  used  1--2×  daily  as  adjunct  treatment
or  allergic  rhinitis.80 Clinical  observation  recommends  prior
asal  lavage  before  the  administration  of  other  nasal  topical
edications.
Biological  agents  (human  or  humanized  monoclonal  anti-
odies)  developed  for  the  treatment  of  severe  asthma  have
een  used  with  good  results  in  other  diseases,  such  as
hronic  urticaria,  chronic  rhinosinusitis,  nasal  polyposis  and
llergic  rhinitis.  They  have  been  synthesized  by  living  orga-
isms  and  directed  against  a  specific  target,  for  instance,
 cytokine  or  its  receptor.81 The  identification  of  different
olecular  pathways  that  have  clinical  significance  helped
stablish  the  treatment  targets  and  led  to  the  identification
f  the  described  endotypes  in  asthmatics  and  that  could  well
e  transferred  to  allergic  rhinitis.82
In  allergic  diseases  the  targets  against  which  biolog-
cal  agents  have  been  developed  are:  IgE,  Th2-response
ytokines,  such  as  IL-4,  IL-5,  IL-9,  IL-13,  IL-31,  and  TSLP,
CR4  chemokine  receptor,  and  surface  adhesion  molecules
D2,  CD11a,  CD20,  CD25,  CD52,  and  ligand  OX40.  However,
here  is  little  evidence  of  the  use  of  biologicals  in  allergic
hinitis.
A  meta-analysis  evaluated  the  efficacy  and  safety  of  oma-
izumab  in  patients  with  uncontrolled  allergic  rhinitis  and
erified  that  it  achieved  significant  symptom  relief,  reduced
se  of  rescue  medication,  and  quality  of  life  improvement
n  these  patients.83 Omalizumab  is  generally  well  tolerated
nd  its  re-administration  is  not  followed  by  the  formation  of
ntibodies  against  the  medication  and,  therefore,  it  is  not
mmunogenic.84 Moreover,  the  addition  of  anti-IgE  agents  to
pecific  allergen  immunotherapy  reduced  the  rate  of  sys-
emic  reactions  to  SIT.85--87
Biologicals  including  anti-IL-5  (mepolizumab,
eslizumab),  anti-IL4/13  (dupilumab)  were  studied  in
atients  with  different  conditions,  but  efficacy  was  not
erified  in  all  patients.  The  target  of  these  biologicals  are
pecific  molecules  that  participate  in  the  pathogenetic
echanisms  of  asthma,  rhinitis,  atopic  dermatitis  and
hronic  rhinosinusitis.88 What  is  expected  is  the  disease
ontrol  through  the  reduction  of  immunological  inflamma-
ion  and  production  of  IgE  antibodies.  Studies  designed  to
valuate  the  action  of  these  therapeutic  resources  having
llergic  rhinitis  as  the  primary  outcome  are  required.89
linical  control  assessment
imilar  to  what  was  observed  in  several  chronic  diseases,
uch  as  asthma  and  chronic  urticaria,  the  concept  of  clinical
ontrol  in  rhinitis  has  been  appreciated  in  recent  years.  This
oncept  can  be  defined  as  the  level  at  which  the  disease
anagement  objectives  are  achieved  by  the  implemented
reatment.90In  contrast  to  the  disease  severity  level,  a  criterion
lassically  used  to  define  the  treatment  of  rhinitis,2 rhini-
is  control  seems  to  be  a  more  adequate  criterion  to
uide  its  treatment.90 However,  the  assessment  of  disease
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Allergic Rhinitis Diagnosis
Persistent
Moderate/severe
Oral anti-H1 or
nasal anti-H1 or
antileukotrienes
aNasal corticosteroids or oralanti-
H1 or nasal anti-H1 or
Antileukotrienes or nasal
corticosteroids + nasal
azelastineb
cNasal corticosteroids or nasal
corticosteroids + oral anti-
H1 or oral anti-h1b or nasal
anti-h1 or Antileukotrienes 
Reassess patient after 2-4 weeks 
Failure:
Review diagnosis, adherence
and investigate infection or other
causes
Failure:
Review diagnosis, adherence
and investigate infection or other
causes
Short oral decongestant
or oral corticosteroids
course
Refer to specialist
Specific immunotherapy 
Anti-H1 - antihistamine; cort. - corticosteroid; a - without order of preference; b – older than 6 years; c - in order of preference; d – older than
18 years
 Rescue medication: oral anti-H1/ anti-H1 with oral decongestant/ corticosteroids  
Failure:
Review diagnosis, adherence
and investigate infection or other
causes
Increase treatment 
Improvement:
Maintain treatment
Association of two or more:
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oral anti-H1/ antileukotrienes +
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for 1 month 
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RFigure  1  Treatment  fl
control  should  be  personalized  and  there  is  no  substitute
for  adequate  follow-up  of  allergic  rhinitis  in  the  context
of  the  physician--patient  relationship.  Several  tools  have
been  developed  with  the  aim  of  assisting  the  evaluation
of  rhinitis  control  by  physicians  and/or  in  the  screening
of  patients  not  controlled  in  the  primary  care.90,91 These
include  the  visual  analog  scale  (VAS)  and  assessment  ques-
tionnaires/scores.  The  VAS  has  recently  been  proposed  by
some  medical  organizations  and  societies  as  a  tool  for  rou-
tine  patient  self-evaluation  and  as  an  auxiliary  method  for
the  pharmacological  treatment  management.4,92,93
The  most  recently  proposed  control  assessment  ques-
tionnaires/scores  differ  in  the  focus  given  to  the  concept
of  control,  either  by  more  intensely  addressing  the  disease
symptoms,  or  by  assessing  the  impact  of  the  consequences
of  rhinitis  on  activities  of  daily  living.  Additionally,  specific
questionnaires  for  the  evaluation  of  rhinitis  and  question-
naires  that  address  both  rhinitis  and  asthma  have  been
developed.  These  include:  Rhinitis  Control  Assessment  Test
(RCAT)94,95;  Rhinitis  Control  Scoring  System  (RCSS)96 and  the
Allergic  Rhinitis  Control  Test.97 The  Control  of  Allergic  Rhini-
tis  and  Asthma  Test  (CARAT)  was  designed  to  jointly  evaluate
the  control  of  adolescent  and  adult  patients  with  asthma  and
rhinitis98 and  the  Control  of  Allergic  Rhinitis  and  Asthma  Test
--  Kids  (CARATkids)  for  children  aged  6--12  years.99
Surgical  treatment
Surgical  treatment  of  allergic  rhinitis  aims  to  correct  the
associated  chronic  nasosinusal  anatomical  changes.  This  is
especially  true  for  patients  with  nasal  obstruction  refrac-
tory  to  clinical  treatment  and  those  who  exhibit  inferior
turbinate  hypertrophy.41 The  benefits  reported  by  observa-
tional  studies  indicate  potential  improvement  in  breathingart  for  allergic  rhinitis.
nd  consequent  improvement  in  quality  of  life,  as  well
s  better  distribution  of  topical  medications  in  the  nasal
avity.40
To  date,  no  technique  has  been  established  as  the  gold
tandard.  The  selection  of  the  technique  to  be  employed
s  individualized  and  depends  on  factors  such  as:  greater
r  lesser  boney  or  mucosal  components  of  the  inferior
urbinate,  surgeon’s  experience,  available  equipment,  and
ost,  among  others.100
inal considerations
ased  on  the  recommendations  for  the  treatment  of  aller-
ic  rhinitis  published  by  the  ARIA  initiative2,4,5 and  by  the
uropean  Academy  of  Allergy  and  Immunology  and  the  Amer-
can  Academy  of  Asthma,  Allergy  and  Immunology9 and  the
merican  Academy  of  Otorhinolaryngology,40 we  proposed
he  flowchart  for  the  treatment  of  allergic  rhinitis  (Fig.  1).
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